Is Trxade Health Stock (MEDS) a Good Investment?
Learn more about Trxade Health Inc’s (MEDS) stock grades for Momentum, Estimate Revisions and Quality and determine whether this Online Services stock meets your investment needs.
Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services, . The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.
Commentary & Analysis
Financial Summary
| Share Statistics | MEDS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.4 | $1,968.0 | 2% |
|
| Shares Out (Mil) | 2.6 | 77.7 | 9% |
|
| Institutional Ownership | 6.5% | 86.6% | 5% |
|
| Float (Mil) | 0.9 | 52.1 | 2% |
|
| Beta | na | 0.75 | na |
|
| Avg Daily Volume (000s) | 241 | 612 | 46% |
|
| Price Change (52-week) |
(96.7%) | 79.8% | 2% |
|
| Growth | MEDS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 10.9% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 0.3% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (17.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MEDS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $1,504 | 8% |
|
| Net Income (TTM) (Mil) | ($88) | $28 | 12% |
|
| EPS (TTM) | ($43.726) | $0.200 | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($14) | $162 | 18% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $9 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $338 | 30% |
|
| Enterprise Value (Q1) (Mil) | $34 | $2,416 | 14% |
|
| Valuation | MEDS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.82 | na |
|
| P/E | na | 26.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MEDS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (90.6%) | 27.8% | 2% |
|
| Net Margin | na | 1.2% | na |
|
| ROA | (203.0%) | 2.2% | 2% |
|
| ROE | 949.3% | 7.2% | 100% |
|
| Liabilities to Assets | 159.5% | 58.6% | 98% |
|
| F-Score | 2 | 5 | 7% |
|
DataMEDS AI, Inc. did not pass any screens on 8/21/2026.
